System

Description of regional surveillance and national surveillance systems contributing to Flu News Europe

The joint European Centre for Disease Prevention and Control (ECDC)–WHO Regional office for Europe Flu News Europe bulletin describes and comments on influenza activity in the 50 Member States (MS) with routine influenza surveillance systems in the WHO European Region. The bulletin provides integrated information on the timing, spread, prevalence and characteristics of circulating viruses, impact and severity of seasonal influenza at the regional level and in the context of global activity. This information is targeted to public health specialists and clinicians to inform decision making, including influenza vaccine strain selection.

Flu News Europe is published on a weekly basis during the influenza season (week 40 to week 20 of the following year) and monthly thereafter to week 39.Quantitative and qualitative epidemiological and virological data are reported to The European Surveillance System (TESSy) hosted by ECDC, after which it is analysed and presented in the bulletin. The majority of countries provide influenza surveillance data to TESSy from more than one surveillance system; all national surveillance systems are summarised in the table below and full details can be found in the country, territory or area profiles available in English and Russian (see links below).

Surveillance of mild disease due to influenza (influenza-like illness (ILI) and acute respiratory infections (ARI)) in the majority of MS is based on nationally organized sentinel networks of primary care physicians, mostly general practitioners (GPs), covering at least 1–5% of the population in their countries. Depending on the MS, physicians report the weekly number of patients seen with ILI and/or ARI, or both, age-groups, to the National Focal Point for influenza. Some MS collect data on ILI or ARI from all health facilities in the MS (universal surveillance). A subset of specimens from sentinel ILI and ARI patients is tested for influenza, both influenza types A and B and influenza subtypes (A(H1N1)pdm09 and A(H3N2). Some MS also determine the lineage (B/Victoria or B/Yamagata) of influenza B viruses and most report on additional semi-quantitative indicators of influenza activity at national level: intensity, geographical spread, trend, impact and dominant virus (see indicator definitions below).

Regarding the surveillance of severe disease associated with influenza, 16 MS in mainly the eastern part of the Region conduct sentinel surveillance for hospitalized cases presenting with Severe Acute Respiratory Infection (SARI), according to standard case definitions. Depending on the MS, all or a subset of SARI patients are tested for influenza virus infection and for the majority of influenza viruses, the influenza type and subtype is determined. Thirteen MS, mainly in the western part of the Region, reported laboratory-confirmed influenza-positive cases from intensive care units (ICU) and/or other wards to TESSy during the 2017/18 season. Case definitions, populations under surveillance and data formats differ among these MS and some do not provide data on influenza A subtypes. The description of the severity of the season is augmented with data from the EuroMOMO project, which monitors all-cause excess mortality among a network of MS or regions.

National influenza centres (NICs) are institutions designated by Ministries of Health and recognized by WHO to participate in the work of the WHO Global Influenza Surveillance and Response System. NICs, and other nationally recognised influenza laboratories, receive respiratory specimens from a range of sources in their countries (both sentinel and so-called non-sentinel sources, such as hospitals, schools, primary care facilities not involved in sentinel surveillance, or nursing homes and similar settings where influenza outbreaks might occur). These laboratories collate and generate data on the virus characteristics of circulating influenza viruses according to influenza type and subtype (A(H3N2) and A(H1N1)pdm09) or lineage (B/Victoria or B/Yamagata). However, in contrast to influenza-positive specimens from sentinel sources, large proportions of both influenza types from non-sentinel sources are not subtyped or ascribed to a lineage.

NICs in the WHO European Region also conduct genetic characterization of viruses to determine the extent of their similarity to viruses included in seasonal influenza vaccines. With increased ease and availability of gene sequencing, greater numbers of influenza-positive clinical specimens and some influenza isolates recovered therefrom (from both sentinel and non-sentinel sources), are genetically characterized. The prevalence of mutations to be associated with reduced susceptibility to antiviral drugs, is also determined by pheno-and genotype.

In addition, many laboratories conduct preliminary antigenic analyses of influenza viruses, isolated in their laboratories, using a limited range of post-infection ferret antisera raised against influenza reference and vaccine viruses (ferret antibody responses being similar to those of humans). These analyses are performed using haemagglutination inhibition (HI) assays and assist laboratories in deciding which viruses to share with a WHO Collaborating Centre (WHO CC) for Reference and Research on Influenza. However, due to the nature of HI there is considerable variation between laboratories and in recent years interpretation of HI data has become challenging with the range of seasonal influenza viruses currently circulating. For these reasons antigenic data reported to TESSy is currently not included in Flu News Europe. Detailed antigenic characterization with wider panels of antisera by HI and virus neutralisation (VN) assays is carried out by the WHO CC and reported in ECDC’s monthly characterisation reports . MS can provide further insight into the national situation through the use of free text fields submitted to TESSy, which are particularly key for defining the start of the season (using national criteria), describing outbreaks in closed settings and for providing context and caveats to submitted data.

 

Useful links

Self-reported country, territory or area surveillance profiles in English and Russian (2017 update)

National influenza bulletins

 

Definitions of Qualitative indicators

 

Intensity of influenza activity is described as:

  • low = no activity or activity at baseline* level;
  • medium = usual level of activity;
  • high = higher level of activity than usual;
  • very high = exceptionally high level of activity.

* Baseline influenza activity is the level at which clinical influenza activity remains throughout the summer and most of the winter.

 

Geographical spread is described as:

 

  • no activity: either no laboratory-confirmed cases or no evidence of increased or unusual respiratory disease activity;
  • sporadic: isolated cases of laboratory-confirmed influenza virus infection;
  • localized: laboratory-confirmed influenza virus infection limited to one administrative unit in the country (or reporting site);
  • regional: laboratory-confirmed influenza virus infection appearing in multiple but less than 50% of the administrative units of the country (or reporting sites);or
  • widespread: laboratory-confirmed influenza virus infection appearing in 50% or more of the administrative units of the country (or reporting sites).

 Trend is described as:

  • increasing: evidence that the level of respiratory disease activity is higher than in the previous week;
  • stable: evidence that the level of respiratory disease activity is similar to that in the previous week;or
  • decreasing: evidence that the level of respiratory disease activity is lower than in the previous week.

 Dominant type is assessed based on data from sentinel and non-sentinel sources.

 

 

Table. Types of influenza surveillance systems conducted in countries, territories or areas in the WHO European Region 

 

Country, territory or area

Primary care syndromic surveillance

Hospital surveillance

 

Non-sentinel

ILI

ARI

SARI

Laboratory-confirmed influenza

Albania

X

X

X

 

X

Armenia

 X

X

X

 

X

Austria

X

 

 

 

X

Azerbaijan

X

X

X

 

 

Belarus

X

X

X

 

X

Belgium

X

X

X

 

X

Bosnia and Herzegovina

X

X

X

 

 

Bulgaria

 

X

 

 

X

Croatia

X

 

 

 

 

Cyprus

X

X

 

X

X

Czech Republic

X

X

 

X

X

Denmark

X

 

 

 

X

Estonia

X

X

 

X

X

Finland

X

X

 

X

X

France

X

 

 

X

X

Georgia

 X

 

X

 

X

Germany

 

X

 

 

X

Greece

X

 

X

X

 

Hungary

X

 

 

 

X

Iceland

X

X

 

X

X

Ireland

X

 

 

X

X

Israel

X

 

 

 

X

Italy

X

 

 

X

X

Kazakhstan

X

X

X

 

 

Kyrgyzstan

X

X

X

X

X

Latvia

X

X

 

 

X

Lithuania

X

X

 

 

X

Luxembourg

X

X

 

 

X

Malta

X

 

 

 

X

Montenegro

X

 

X

 

 

Netherlands

X

X

X

X

X

Norway

X

X

 

X

X

Poland

X

 

 

 

X

Portugal

X

 

 

X

X

Republic of Moldova

X

X

X

 

X

Romania

X

X

x

 

x

Russian Federation

X

X

X

 

x

Serbia

X

 

X

 

X

Slovakia

X

X

X

 

X

Slovenia

X

X

 

 

X

Spain

X

 

 

X

X

Sweden

 

 

 

X

X

Switzerland

X

 

 

 

X

Tajikistan

X

X

X

 

 

The former Yugoslav Republic of Macedonia

X

X

X

 

X

Turkey

X

 

X

 

X

Turkmenistan

X

 X

X 

X

X

Ukraine

X

X

X

 

X

United Kingdom

 

 

 

 

 

England

X

   

X

X

Northern Ireland

X

 

 

X

X

Sotland

X

 

 

X

X

     Wales

X

X

 

X

X

Uzbekistan

X

X

X

 

 

 

[Source: self-reported information collected for the 2017 and 2018 version of the country, territory and are influenza surveillance profiles, as availability allows on 11/10/2018]